Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, dermatology, diabetology, gastroenterology, haematology, neurology, ophthalmology, rheumatology, and urology, as well as respiratory, psychiatry, probiotics, orthopedics, oral anti diabetes drug, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppressant, hepatoprotectives, helminthics, fever, and emollients/protectives. It exports its products to approximately 100 countries worldwide. The company was incorporated in 1949 and is based in Mumbai, India.
Year | Receivables | Debt | Liabilities | Assets | Current Assets |
---|---|---|---|---|---|
2023 | 201.82 M | 135.85 M | 401.56 M | 1.32 B | 659.16 M |
2022 | 118.08 M | 26.59 M | 322.64 M | 1.03 B | 617.56 M |
2021 | 147.27 M | 63.31 M | 246.35 M | 909.07 M | 530.43 M |
2020 | 128.9 M | 11.83 M | 160.92 M | 722.17 M | 409.02 M |
2019 | 132.54 M | 52.63 M | 192.64 M | 625.95 M | 339.85 M |